GlaxoSmithKline plc to Post FY2022 Earnings of $3.75 Per Share, Jefferies Group Forecasts (GSK)

GlaxoSmithKline plc (NYSE:GSK) – Jefferies Group issued their FY2022 EPS estimates for shares of GlaxoSmithKline in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford forecasts that the pharmaceutical company will earn $3.75 per share for the year.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.01. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%.

A number of other analysts have also recently commented on the company. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Wednesday, October 18th. UBS Group upgraded GlaxoSmithKline from a “neutral” rating to a “buy” rating and upped their price objective for the company from $35.04 to $35.85 in a research report on Monday, November 27th. TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, October 24th. Finally, Argus reduced their price objective on GlaxoSmithKline to $40.00 and set a “buy” rating for the company in a research report on Thursday, November 30th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $38.57.

GlaxoSmithKline (NYSE GSK) traded up $0.01 during trading on Wednesday, reaching $38.17. The company had a trading volume of 4,320,000 shares, compared to its average volume of 5,510,000. The stock has a market capitalization of $93,210.00, a PE ratio of 29.14, a PEG ratio of 2.17 and a beta of 0.97. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. GlaxoSmithKline has a 12 month low of $34.52 and a 12 month high of $44.53.

A number of institutional investors and hedge funds have recently modified their holdings of GSK. Principal Financial Group Inc. purchased a new stake in GlaxoSmithKline in the second quarter worth about $602,000. King Luther Capital Management Corp increased its position in GlaxoSmithKline by 1.0% in the second quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after buying an additional 55 shares in the last quarter. Stevens Capital Management LP increased its position in GlaxoSmithKline by 17.1% in the second quarter. Stevens Capital Management LP now owns 40,674 shares of the pharmaceutical company’s stock worth $1,754,000 after buying an additional 5,933 shares in the last quarter. Lazard Asset Management LLC increased its position in GlaxoSmithKline by 5.8% in the second quarter. Lazard Asset Management LLC now owns 42,698 shares of the pharmaceutical company’s stock worth $1,841,000 after buying an additional 2,324 shares in the last quarter. Finally, Quantitative Investment Management LLC purchased a new stake in GlaxoSmithKline in the second quarter worth about $3,221,000. Institutional investors and hedge funds own 9.80% of the company’s stock.

In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of GlaxoSmithKline stock in a transaction on Monday, November 6th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.00% of the company’s stock.

The business also recently declared a quarterly dividend, which was paid on Thursday, January 11th. Shareholders of record on Friday, November 10th were given a $0.5037 dividend. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a yield of 5.28%. GlaxoSmithKline’s dividend payout ratio is presently 155.73%.

WARNING: “GlaxoSmithKline plc to Post FY2022 Earnings of $3.75 Per Share, Jefferies Group Forecasts (GSK)” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/18/glaxosmithkline-plc-to-post-fy2022-earnings-of-3-75-per-share-jefferies-group-forecasts-gsk.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History and Estimates for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply